GLP-1 medicines are increasingly being prescribed to some children for weight loss, adding a new dimension to the debate over how physicians should treat childhood obesity. Dr. Rhea Rogers, a board-certified physician and host of Aging Untold, said some patients may need medication when changes to diet and physical activity do not produce enough progress.
The issue is unfolding alongside efforts to promote healthier habits among children. Students at Magnolia Woods Elementary in Baton Rouge, Louisiana, are learning about eating and exercise as part of a statewide campaign intended to reduce obesity rates. But Rogers said lifestyle measures alone do not always address the biological factors affecting a child’s weight.
“Sometimes that just move more and eat less is not enough because you have genetics and all that.”
Rogers described the underlying problem as a form of hormonal dysregulation in patients who become significantly overweight. She said GLP-1 agonists can reduce what she called persistent preoccupation with food and may have anti-inflammatory effects. Those descriptions reflect the physician’s comments, rather than evidence in the material establishing that the medicines are appropriate for every child with obesity.
Eligibility depends on age and clinical history
The information presented identifies age 10 and older as a possible threshold for children being treated for diabetes. For weight-loss treatment, experts cited a different set of considerations: a child may be considered a candidate when their BMI is at or above the 95th percentile and lifestyle changes have not been effective.
The assessment may also involve health problems associated with obesity, including hormone-related conditions that require medical intervention. The criteria described are not a blanket recommendation. They point instead to the need for an individualized evaluation of a child’s medical condition, treatment history and potential risks.
- Some children may receive GLP-1 medicines after diet and exercise changes have not been sufficient.
- Weight-loss candidates may include children at or above the 95th BMI percentile.
- Age requirements can differ depending on whether treatment is for diabetes or weight loss.
Rogers cautioned against viewing the medicines as a standalone answer. “It’s not a miracle drug — it’s a tool, and so you have to treat the whole entire scenario,” she said. That approach places medication within a wider program involving nutrition, physical activity and medical supervision.
Affordability remains a barrier
The cost of GLP-1 medicines remains a significant obstacle for families. The material does not provide a price or specify insurance coverage, but it says that some patients cannot afford the drugs or choose not to take them. For those families, the alternatives described are balanced meals and a healthy lifestyle.
The growing use of these medicines in children therefore involves more than demand for a popular class of weight-loss treatments. It also raises questions about which patients should receive them, how treatment should be integrated with broader care and whether families can sustain access. The information provided emphasizes that decisions about a child’s treatment should be made with a licensed physician or another qualified health professional.
